UBS Group’s CTI BioPharma CTIC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-402,893
Closed -$1.69M – 10428
2023
Q1
$1.69M Sell
402,893
-523,416
-57% -$2.72M ﹤0.01% 3600
2022
Q4
$5.57M Buy
926,309
+782,053
+542% +$4.27M ﹤0.01% 2399
2022
Q3
$840K Sell
144,256
-133,244
-48% -$830K ﹤0.01% 3901
2022
Q2
$1.66M Buy
277,500
+260,766
+1,558% +$1.34M ﹤0.01% 3309
2022
Q1
$78K Buy
16,734
+12,717
+317% +$37.9K ﹤0.01% 6094
2021
Q4
$10K Sell
4,017
-261
-6% -$639 ﹤0.01% 8872
2021
Q3
$13K Sell
4,278
-2,469
-37% -$6.72K ﹤0.01% 7731
2021
Q2
$17K Sell
6,747
-3,224
-32% -$7.73K ﹤0.01% 7551
2021
Q1
$29K Buy
9,971
+5,693
+133% +$18.6K ﹤0.01% 7059
2020
Q4
$14K Sell
4,278
-584
-12% -$1.94K ﹤0.01% 7258
2020
Q3
$10K Sell
4,862
-21,000
-81% -$26.8K ﹤0.01% 6904
2020
Q2
$30K Buy
25,862
+8,195
+46% +$8.66K ﹤0.01% 6288
2020
Q1
$16K Buy
17,667
+8,263
+88% +$9.47K ﹤0.01% 6662
2019
Q4
$15K Buy
9,404
+5,328
+131% +$5.05K ﹤0.01% 7074
2019
Q3
$3K Sell
4,076
-4,109
-50% -$3.14K ﹤0.01% 7707
2019
Q2
$7K Buy
8,185
+2,255
+38% +$2.08K ﹤0.01% 7295
2019
Q1
$6K Sell
5,930
-26,451
-82% -$27.9K ﹤0.01% 7134
2018
Q4
$24K Buy
32,381
+6,576
+25% +$10.8K ﹤0.01% 6660
2018
Q3
$56K Buy
25,805
+5,398
+26% +$13.4K ﹤0.01% 6084
2018
Q2
$101K Buy
20,407
+5,252
+35% +$23K ﹤0.01% 5440
2018
Q1
$59K Buy
15,155
+3,979
+36% +$14K ﹤0.01% 5593
2017
Q4
$30K Buy
11,176
+3,973
+55% +$11.6K ﹤0.01% 6252
2017
Q3
$23K Buy
7,203
+2,865
+66% +$9.6K ﹤0.01% 6369
2017
Q2
$14K Sell
4,338
-479
-10% -$1.86K ﹤0.01% 6584
2017
Q1
$20K Sell
4,817
-3,867
-45% -$17.8K ﹤0.01% 6155
2016
Q4
$35K Sell
8,684
-532
-6% -$2.21K ﹤0.01% 6127
2016
Q3
$34K Buy
9,216
+7,791
+547% +$28.4K ﹤0.01% 5829
2016
Q2
$5K Buy
1,425
+1,319
+1,244% +$6.05K ﹤0.01% 7191
2016
Q1
$1K Sell
106
-965
-90% -$7.71K ﹤0.01% 7546
2015
Q4
$13K Buy
1,071
+935
+688% +$12.5K ﹤0.01% 7150
2015
Q3
$2K Hold
136
– – ﹤0.01% 8163
2015
Q2
$3K Sell
136
-4,369
-97% -$84.3K ﹤0.01% 8149
2015
Q1
$81K Buy
4,505
+3,538
+366% +$79.6K ﹤0.01% 5606
2014
Q4
$23K Buy
+967
New +$22.4K ﹤0.01% 7497

Other funds holding CTIC

UBS Group's CTIC Position: Q2 2023 in Review

UBS Group sold out of CTI BioPharma (CTIC) in Q2 2023, closing a stake of 402,893 shares — an estimated $1.69M sold.

UBS Group first reported a position in CTIC in Q4 2014 and held it in 34 quarters. The position peaked at $5.57M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

  • UBS Group reported no remaining CTI BioPharma position as of Q2 2023 after selling out during the quarter.
  • UBS Group sold 402,893 CTI BioPharma shares in Q2 2023, an estimated $1.69M.
  • UBS Group first reported a position in CTI BioPharma in Q4 2014 and held it in 34 quarters.
  • UBS Group's CTI BioPharma position peaked at $5.57M in Q4 2022.
  • 2 funds tracked by Wall St. Rank held CTI BioPharma as of Q2 2023.

Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.